CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

Pharmgenomics Pers Med · 2018 · PMC5846312 · PMID 29563827

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

As expected, the CYP3A5 expressers showed a trend for higher tacrolimus dose requirement compared to nonexpressers.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.